Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Statin Side Effects: What the Evidence Shows (opens in a new tab)

medscape.com · 2026-10-05

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 4 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Four of six claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 4 supported
  • 2 not covered
Open claim evidence
3
Source paper

Source layer

The 11 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredThe article says muscle symptoms are causally related to statins, but the absolute excess is small and concentrated in the first year: about 11 additional muscle-related events per 1000 person-years, with more than 90% of reported muscle complaints in trials not attributable to the statin.View evidenceHide evidence

As stated11 additional muscle-related events per 1000 person-years in year 1

Why this verdict

The abstract-level profile supports the broad point that muscle-related outcomes were observed/supported in blinded randomized-trial data. However, the specific first-year excess of about 11 events per 1000 person-years and the statement that more than 90% of reported muscle complaints were not attributable to statins are not reported in the supplied abstract-level profile.

1

Study evidence

Abnormal liver transaminases were increased with statin therapy relative to placebo in blinded randomized trials.RR 1.41 (95% CI 1.26–1.57)

“we aimed to assess the evidence for such undesirable effects more reliably through a meta-analysis of individual participant data from large double-blind trials of statin therapy”
Claim 2 of 6Not coveredThe article reports that statins increase the risk of newly diagnosed diabetes in a dose-dependent way, with a relative risk of 1.10 for low- or moderate-intensity therapy and 1.36 for high-intensity therapy.View evidenceHide evidence

As statedRR 1.10 low/moderate, 1.36 high-intensity

Why this verdict

The profile supports that diabetes was among previously reported statin-associated outcomes observed in the blinded trial data, but the abstract-level evidence supplied here does not provide the stated diabetes rate ratios of 1.10 and 1.36 or a diabetes-specific dose-response analysis. Unit 0002 supports dose-dependence for liver-test abnormalities, not the specific diabetes estimates.

1

Study evidence

Abnormal liver transaminases were increased with statin therapy relative to placebo in blinded randomized trials.RR 1.41 (95% CI 1.26–1.57)

“we aimed to assess the evidence for such undesirable effects more reliably through a meta-analysis of individual participant data from large double-blind trials of statin therapy”
2

Study evidence

More intensive versus less intensive statin regimens showed a statistically significant excess of abnormal liver transaminases.

“involved a double-blind comparison of statin versus placebo or of a more intensive versus a less intensive statin regimen”
Claim 3 of 6SupportedA CTT meta-analysis in The Lancet questioned many widely cited statin side effects, while confirming that some effects on muscles, the liver, and glucose metabolism can occur; the article says the magnitude is usually much lower than public criticism suggests.View evidenceHide evidence

As statedusually significantly lower than what the public criticism of these drugs would suggest

Why this verdict

The abstract-level profile supports the main framing: an IPD meta-analysis of large double-blind randomized statin trials found that most product-label adverse outcomes were not supported by FDR-significant excesses, while muscle outcomes, diabetes, and liver-test abnormalities were supported. The profile also supports that several absolute excesses were small. The comparison with 'public criticism' is more journalistic than directly evidenced in the abstract, but it does not materially change the supported core claim.

1

Study evidence

Abnormal liver transaminases were increased with statin therapy relative to placebo in blinded randomized trials.RR 1.41 (95% CI 1.26–1.57)

“we aimed to assess the evidence for such undesirable effects more reliably through a meta-analysis of individual participant data from large double-blind trials of statin therapy”
2

Study evidence

More intensive versus less intensive statin regimens showed a statistically significant excess of abnormal liver transaminases.

“involved a double-blind comparison of statin versus placebo or of a more intensive versus a less intensive statin regimen”
Claim 4 of 6SupportedOf 66 package-insert adverse events examined, only four remained statistically significant after adjustment: elevated transaminase levels, other liver function test abnormalities, changes in urine composition, and edema.View evidenceHide evidence

As stated4 of 66 events

Why this verdict

The profile says the authors screened SmPC-listed undesirable outcomes and that four additional SmPC-listed outcomes were FDR-significant in statin-versus-placebo trials: abnormal liver transaminases, other liver function test abnormalities, urinary composition alteration, and oedema. The paper profile describes this as multiplicity control via a 5% false discovery rate, not adjustment for confounding; the claim is supported if 'adjustment' refers to that statistical multiplicity control.

1

Study evidence

Abnormal liver transaminases were increased with statin therapy relative to placebo in blinded randomized trials.RR 1.41 (95% CI 1.26–1.57)

“we aimed to assess the evidence for such undesirable effects more reliably through a meta-analysis of individual participant data from large double-blind trials of statin therapy”
2

Study evidence

An outcome dictionary of ‘undesirable effect’ terms was compiled from statin SmPCs via an electronic medicines compendium search of five statins and used to prespecify the adverse-event outcomes tested in the IPD meta-analysis.

“we generated a list of all undesirable effect terms listed in statin SmPCs by searching an electronic medicines compendium for five statins (atorvastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin)”
Claim 5 of 6SupportedThe article says there is no reliable evidence from large blinded randomized trials that statins increase cognitive impairment, depression, or sleep disturbances.View evidenceHide evidence

Why this verdict

The profile explicitly states that most other product-label conditions, including cognitive impairment, depression, and sleep disturbance, did not show FDR-significant excesses in the large double-blind randomized trials. The story’s wording, 'no reliable evidence from large blinded randomized trials,' matches that abstract-level conclusion.

1

Study evidence

Abnormal liver transaminases were increased with statin therapy relative to placebo in blinded randomized trials.RR 1.41 (95% CI 1.26–1.57)

“we aimed to assess the evidence for such undesirable effects more reliably through a meta-analysis of individual participant data from large double-blind trials of statin therapy”
Claim 6 of 6SupportedThe article says liver enzyme elevations do occur with statins and appear dose dependent, but the annual excess risk for abnormal liver function tests is only about 0.13%.View evidenceHide evidence

As statedannual excess risk for abnormal liver function tests is only about 0.13%

Why this verdict

The profile reports FDR-significant excesses for abnormal liver transaminases and other liver function test abnormalities, an absolute annual excess for combined liver function test abnormalities of about 0.13%, and significant excesses in the more-intensive versus less-intensive comparison supporting dose-dependence. The causal framing is consistent with blinded randomized-trial evidence and the paper profile’s interpretation.

1

Study evidence

Abnormal liver transaminases were increased with statin therapy relative to placebo in blinded randomized trials.RR 1.41 (95% CI 1.26–1.57)

“we aimed to assess the evidence for such undesirable effects more reliably through a meta-analysis of individual participant data from large double-blind trials of statin therapy”
2

Study evidence

More intensive versus less intensive statin regimens showed a statistically significant excess of abnormal liver transaminases.

“involved a double-blind comparison of statin versus placebo or of a more intensive versus a less intensive statin regimen”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Dose-intensity analysis supported liver-test abnormalities but did not show significant excesses for urinary composition alteration or oedema.

    The story reports urinary composition alteration and oedema as statistically significant main-analysis signals but does not mention the limiting nuance that these were not supported in the more-intensive versus less-intensive comparison.

    From IPD meta-analysis of double-blind RCTs: more intensive vs less intensive statin regimens

  • The intensive-versus-less-intensive analysis was based on four trials, and the abstract does not provide numeric rate ratios or event counts for that subset.

    This abstract-level limitation is not included in the story’s caveats.

    From IPD meta-analysis of double-blind RCTs: more intensive vs less intensive statin regimens

5 things the story did carry across
  • Primary evidence base: individual participant data meta-analysis of large double-blind randomized trials, including 19 statin-versus-placebo trials with 123,940 participants and median follow-up of 4.5 years, using FDR control at 5%.
  • The paper tested adverse outcomes derived from statin product-label/SmPC undesirable-effect terms.
  • Only four additional SmPC-listed outcomes were FDR-significant in the main statin-versus-placebo analysis: abnormal liver transaminases, other liver function test abnormalities, urinary composition alteration, and oedema.
  • Most other product-label outcomes, including cognitive impairment, depression, sleep disturbance, and peripheral neuropathy, were not supported by FDR-significant excesses in the blinded randomized trials.
  • Liver-test abnormalities were increased with statins, had low absolute annual excess risk, and dose-intensity comparisons supported dose-dependence.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataRe-assess which adverse effects listed on statin product labels are causally attributable to statins using an individual participant data (IPD) meta-analysis of large double-blind randomized trials, with multiplicity control (5% FDR).IPD meta-analysis of double-blind randomized controlled trialsExpand

In plain English

IPD meta-analysis of large double-blind randomized trials testing whether adverse outcomes listed in statin product labels are causally attributable to statins. Primary synthesis comprised 19 statin-versus-placebo trials (123,940 participants, median follow-up 4.5 years). Event rate ratios with 95% CIs were estimated and statistical significance assessed controlling the false discovery rate at 5%. Blinded trial data supported effects for muscle outcomes and diabetes (previously reported) and found FDR-significant excesses for four SmPC-listed outcomes (abnormal liver transaminases, other liver function test abnormalities, urinary composition alteration, and oedema); most other listed conditions (including cognitive impairment, depression, sleep disturbance, and peripheral neuropathy) were not supported by FDR-significant excesses.

Key findings

  • Abnormal liver transaminases were increased with statin therapy relative to placebo in blinded randomized trials.RR 1.41 (95% CI 1.26–1.57)
  • Other liver function test abnormalities (beyond transaminases) were increased with statin therapy.RR 1.26 (95% CI 1.12–1.41)
“we aimed to assess the evidence for such undesirable effects more reliably through a meta-analysis of individual participant data from large double-blind trials of statin therapy”
2secondary dataEvaluate whether any detected adverse effects show dose-dependence by comparing more intensive vs less intensive statin regimens in blinded randomized trials.IPD meta-analysis of double-blind RCTs: more intensive vs less intensive statin regimensExpand

In plain English

IPD meta-analysis of four double-blind randomized trials comparing more intensive versus less intensive statin regimens found significant excesses in abnormal liver transaminases and other liver function test abnormalities (consistent with dose-dependence), but no significant excesses for urinary composition alteration or oedema.

Key findings

  • More intensive versus less intensive statin regimens showed a statistically significant excess of abnormal liver transaminases.
  • More intensive versus less intensive statin regimens showed a statistically significant excess of other liver function test abnormalities.
“involved a double-blind comparison of statin versus placebo or of a more intensive versus a less intensive statin regimen”
What this piece can’t prove
  • The intensive-versus-less-intensive comparison is based on four trials; the abstract does not report trial-level sample sizes, event counts, or numeric rate ratios for this subset.

1 further detail could not be confirmed from the summary.

3secondary dataCompile and operationalize the set of ‘undesirable effect’ terms from statin Summaries of Product Characteristics (SmPCs) to define the adverse-event outcomes to be tested in the IPD meta-analysis.document extraction and outcome-term harmonization from SmPCsExpand

In plain English

The authors compiled an outcome dictionary of ‘undesirable effect’ terms by searching an electronic medicines compendium for the SmPCs of five statins (atorvastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin) to define the adverse-event outcomes to be tested in the IPD meta-analysis.

Key findings

  • An outcome dictionary of ‘undesirable effect’ terms was compiled from statin SmPCs via an electronic medicines compendium search of five statins and used to prespecify the adverse-event outcomes tested in the IPD meta-analysis.
“we generated a list of all undesirable effect terms listed in statin SmPCs by searching an electronic medicines compendium for five statins (atorvastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin)”
What this piece can’t prove
  • No description of how SmPC language differences, synonyms, or compound terms were handled or mapped to trial adverse-event coding.

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 26 candidate papers

And 20 more candidates considered.